January 2024 in “IntechOpen eBooks” This study highlights the various bacterial, fungal, and viral threats to honeybee colonies, such as American Foulbrood and Deformed Wing Virus, and discusses management strategies like Integrated Pest Management and genetic resistance to preserve honeybee populations and their crucial pollination roles.
15 citations
,
March 2023 in “Heliyon” This study found that water-soluble beehive extract exhibited anxiolytic, antidepressant, and anti-inflammatory effects in animal models.
This study found that activating KATP channels with pinacidil may reduce antioxidant levels and mortality in honey bees, suggesting a role in regulating antiviral immunity through reactive oxygen species.
2 citations
,
December 2021 This study found that the observed isotropic ss-ECD spectrum of finasteride is influenced by the anisotropy of locally oriented crystals, offering new possibilities for analyzing solid-state chiral materials.
April 2026 in “Zenodo (CERN European Organization for Nuclear Research)” This comprehensive guide from nanotechsci.com explores how nanocrystal technology enhances the bioavailability of poorly water-soluble pharmaceuticals, detailing the science behind crystallization and practical synthesis techniques, and discussing their advanced drug delivery applications across various routes.
January 2025 in “Current Drug Delivery” This study found that compounded formulations using TrichoSol™ and TrichoFoam™ vehicles for alopecia treatments maintained stability and were effective for use up to 180 days, suggesting these vehicles are suitable for personalizing hair care solutions without significant degradation or physical changes.
September 2020 in “Eureka: Health Sciences” In this study, the researchers developed an optimal emulgel formulation for treating androgenic alopecia, determining that a base with 0.3% Carbomer Ultraz 10, 0.1% potassium sorbate, and 0.2% triethanolamine offered the best properties for drug release, application compliance, safety, and stability.
May 2015 in “HAL (Le Centre pour la Communication Scientifique Directe)” In this study, the stability properties of various active pharmaceutical ingredients (APIs) were characterized, revealing how factors like pressure and water sensitivity influence their intrinsic stability and potential degradation.
December 2024 in “PubMed” This study evaluates the compatibility of six active pharmaceutical ingredients, including finasteride and spironolactone, with TrichoFoam™, a foam vehicle used in personalized treatments for alopecia, though it does not report specific results.
February 2022 in “Scientia Pharmaceutica” This study validated that six out of seven tested topical formulations for alopecia are compatible for 6-month use, suggesting they may be practical for compounding pharmacies.
August 2025 in “Journal of Pure and Applied Microbiology” This review discusses various therapeutic properties of bee venom, including its potential against cancer, infections, and inflammatory diseases, but notes limitations in clinical application due to variability and safety concerns, calling for further research.
In this study, researchers assessed the stability of various formulations in the TrichoConcept™ line for customized alopecia treatment. They found that the combinations remained stable from 14 to 180 days, supporting the use of these vehicles for enhancing therapeutic outcomes in hair loss treatments.
2 citations
,
May 2021 in “Journal of pharmaceutical and biomedical analysis” This study utilized a UHPLC-HRMS method to identify eight active pharmaceutical ingredients, such as ketoconazole and minoxidil, in 26 out of 100 analyzed cosmetic products.
April 2026 in “Zenodo (CERN European Organization for Nuclear Research)” This guide explores the fundamental science and practical applications of nanocrystal technologies to enhance the bioavailability of poorly water-soluble drugs, detailing synthesis methods, stability solutions, and drug delivery innovations like hydrogel composites and microneedle platforms.
1 citations
,
October 2020 in “Annales pharmaceutiques françaises” In this study, researchers developed and validated a rapid and robust chromatographic method to assess the concentration of Minoxidil and Finasteride in a new topical formulation for alopecia, demonstrating its ability to distinguish between different types of formulations using in vitro diffusion data.
In this study, researchers reported that hardshell capsules using the DiluCap® line of excipients demonstrated varying dissolution profiles under gastrointestinal-simulating conditions, with minoxidil and finasteride showing rapid release and melatonin and naltrexone displaying controlled release, indicating their suitability for different applications in compounding pharmacies.
1 citations
,
January 2022 in “Electronic Imaging” This study introduces a novel method for digitizing hair color that accurately captures and renders the color appearance of physical hair samples in synthetic images.
6 citations
,
February 2020 in “Journal of Natural Products” In this chemical investigation, cyclospongiaquinone 1 from the sponge Verongula cf. rigida showed strong steroid 5α-reductase inhibitory activity, comparable to that of finasteride.
11 citations
,
October 2001 in “Dermatologic Clinics” In this study, subcutaneous recombinant human IL-12 showed a 43% partial response rate in early-stage mycosis fungoides patients refractory to previous treatments, with generally mild to moderate adverse events reported.
26 citations
,
March 2014 in “International journal of pharmaceutics” This study confirmed that the novel solid lipid microparticle formulation of adapalene demonstrated follicular penetration potential and targeted particle erosion in sebum in in vitro tests.
66 citations
,
February 2010 in “CrystEngComm” Made 8 minoxidil samples; 1 cocrystal, 7 salts formed.
39 citations
,
June 2019 in “Toxins” This review explores the therapeutic potential of bee venom for treating various skin diseases, discussing its mechanisms and effects but reports no new clinical findings.
13 citations
,
February 2015 in “Journal of Pharmaceutical Sciences” This study found that the polymorphic forms I, II, and III of finasteride can be prepared purely, with form III being identical to what was previously referred to as form X.
6 citations
,
September 2024 in “Metabolism and Target Organ Damage” This review discusses the role of skin enzymes in drug metabolism and emphasizes the need for models assessing enzyme activity to evaluate the safety and bioequivalence of topical generic drugs, highlighting efforts to standardize testing protocols for transdermal products.
6 citations
,
June 2000 in “Psychiatric Services” This article discusses the sexual health issues faced by postmenopausal women and highlights the need for more research and tailored treatments, but it reports no new clinical results.
5 citations
,
September 2014 in “Journal of Pharmaceutical Sciences”
January 2026 in “Drug Delivery and Translational Research” This study investigated the integration of crystal engineering and microneedle technology for androgenetic alopecia treatment, finding that microneedles loaded with newly developed Kopexil multicomponent crystals reduced drug diffusion rates in vitro compared to standard formulations.
February 2024 in “International Journal For Multidisciplinary Research” This review examines the advances in nanostructured lipid carriers for treating hyperpigmentation but presents no new clinical results; the authors highlight their potential benefits and applications.
15 citations
,
June 2019 in “Journal of Neuroendocrinology” This study found that isoallopregnanolone reduced stress-induced tic-like behaviors and sensorimotor gating deficits in a mouse model of Tourette syndrome, suggesting potential therapeutic properties comparable to existing treatments like haloperidol and finasteride.
140 citations
,
February 2020 in “Frontiers in Plant Science” This article discusses the potential of RNA-based biopesticides for sustainable agriculture and reports no new experimental results; it highlights the need for improved delivery systems and regulatory development to enhance deployment.